Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Christopher Hillis

Showing results (31-40 of 36) with videos related to

Pageof 4
Sort By:
You have reached the last page of results.This site can display upto 36 results.
BMJ Open|September 13, 2019
Evaluating the endometabolic and bone health effects of Tyrosine Kinase Inhibitors in Chronic Myeloid Leukaemia: a systematic review protocolJanatani Balakumaran, Tanisha Birk, Breanne Golemiec, et al.
BMJ Open Quality|June 11, 2024
Implementation and evaluation of a national quality improvement initiative in cancer surgeryAngel Arnaout, Shaheena Mukhi, Jamie Brehaut, et al.
JACC. Advances|May 23, 2025
Early Cardiovascular Events in Recipients of Allogeneic Hematopoietic Stem Cell TransplantationNazanin Aghel, Vincent Wang, Darryl Leong, et al.
Acta Haematologica|March 5, 2025
ECLIPSE-PV: A Randomized, Multicenter Study to Assess Efficacy, Safety, and Tolerability of Two Dosing Regimens of Ropeginterferon Alfa-2b-Njft in Polycythemia VeraJohn Mascarenhas, Prithviraj Bose, Christopher Hillis, et al.
Frontiers in Medicine|May 7, 2025
A multicenter study to assess efficacy, safety, and tolerability of ropeginterferon alfa-2b-njft in patients with essential thrombocythemia in the US and Canada: EXCEED-ET trialLucia Masarova, Brandi N Reeves, Firas El Chaer, et al.
Lancet Regional Health. Americas|June 17, 2026
Ropeginterferon alfa-2b-njft treatment in essential thrombocythemia across different driver mutations: results from a North American, single-arm, multicentre study (EXCEED-ET)Brandi N Reeves, Firas El Chaer, Lynda Foltz, et al.
Pageof 4

Showing results (31-40 of 36) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 36 results.
BMJ Open|September 13, 2019
Evaluating the endometabolic and bone health effects of Tyrosine Kinase Inhibitors in Chronic Myeloid Leukaemia: a systematic review protocolJanatani Balakumaran, Tanisha Birk, Breanne Golemiec, et al.
BMJ Open Quality|June 11, 2024
Implementation and evaluation of a national quality improvement initiative in cancer surgeryAngel Arnaout, Shaheena Mukhi, Jamie Brehaut, et al.
JACC. Advances|May 23, 2025
Early Cardiovascular Events in Recipients of Allogeneic Hematopoietic Stem Cell TransplantationNazanin Aghel, Vincent Wang, Darryl Leong, et al.
Acta Haematologica|March 5, 2025
ECLIPSE-PV: A Randomized, Multicenter Study to Assess Efficacy, Safety, and Tolerability of Two Dosing Regimens of Ropeginterferon Alfa-2b-Njft in Polycythemia VeraJohn Mascarenhas, Prithviraj Bose, Christopher Hillis, et al.
Frontiers in Medicine|May 7, 2025
A multicenter study to assess efficacy, safety, and tolerability of ropeginterferon alfa-2b-njft in patients with essential thrombocythemia in the US and Canada: EXCEED-ET trialLucia Masarova, Brandi N Reeves, Firas El Chaer, et al.
Lancet Regional Health. Americas|June 17, 2026
Ropeginterferon alfa-2b-njft treatment in essential thrombocythemia across different driver mutations: results from a North American, single-arm, multicentre study (EXCEED-ET)Brandi N Reeves, Firas El Chaer, Lynda Foltz, et al.
Pageof 4